• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Gelatin, Soft Capsule Gelatin, Hard Capsule Gelatin, Pharmaceutical Gelatin-Foodmate
Neohesperidin
Advantame
Cleanroom Bench Horizontal Laminar Flow Hood Airflow Clean Bench
Pharma and Food Grade, USP/FCC Neotame Sweetener E961
Trilobatin

Analysis of 39 New Biological Drugs Marketed in the World in 2018

PharmaSources/XuanyaoFebruary 01, 2019

Tag: Biopharmaceutical , biological drugs , global , 2018

21st century is the century of life sciences. Currently, more than half of members of the United States National Academy of Sciences engage in the life science field; more than half of the U.S. Federal Government’s budget for scientific research is used for life sciences. Therefore, biological drugs are developing faster and faster in human disease therapeutic areas, compared to chemical drugs.

Analysis of 39 New Biological Drugs Marketed in the World in 2018

Biotech drugs are referred to as biological drugs and mainly divided into recombinant protein drugs, recombinant polypeptide drugs, recombinant DNA drugs, and stem cell therapies, etc. It’s estimated that the global biological drug market will reach USD 326 billion in 2022. And Frost&Sullivan forecasts that the Chinese biological drug market will reach a size of RMB 326.9 billion in 2021. Among the 93 new drugs marketed in the world in 2018, there are 54 chemical drugs and 39 biological drugs.

Let’s check the targets and R&D information of those 39 drugs:

S/N

Pharmaceutical product name

Target

R&D company

1

Caplacizumab

vWF

Ablynx

2

Darvadstrocel (TiGenix)

unidentified

TiGenix, Takeda

3

YS-ON-001

unidentified

Yisheng Biopharma

4

Etanercept biosimilar (Mochida)

TNFβ, TNFα

Mochida Pharmaceutical , Ayumi

5

Adalimumab biosimilar

TNFα

Fujifilm Kyowa Kirin Biologics, Mylan

6

Adalimumab biosimilar

TNFα

Sandoz

7

Romosozumab

SO

Amgen, UCB, Astellas

8

Andexanet alfa

PT

Portola Pharmaceutical

9

Pegvaliase-pqpz

Phenylalanine

BioMarin Pharmaceutical

10

Cemiplimab

PD-1

Regeneron Pharmaceuticals , Sanofi

11

Sintilimab

PD-1

Innovent Biologics, Eli Lilly

12

Toripalimab

PD-1

Shanghai Junshi Biosciences, Suzhou Zhonghe

13

Velmanase alfa

Mannose

Zymenex

14

Lanadelumab

KLKB1

Dyax Pharma

15

Meningococcal A/C vaccine (Hualan Biological Bacterin)

Immunostimulator

Hualan Biological Bacterin Co., Ltd.

16

House-dust mite allergy immunotherapy (Lofarma)

Immunomodulator

Lofarma S.p.A, Ajou University School of Medicine

17

tagraxofusp-erzs

IL3RA

Texas A&M University, Stemline

18

Tildrakizumab-asmn

IL23

MSD, Sun Pharmaceutical, Almirall

19

Emapalumab

IFN-γ

NovImmune, SOBI

20

Recombinant cytokine gene derived protein (Genova Biotech)

IFNAR

Genova

21

Trastuzumab biosimilar (Allergan/Amgen)

HER2

Synthon, Allergan, Daiichi Sankyo, Amgen

22

Trastuzumab biosimilar (Pfizer)

HER2

Pfizer

23

Agalsidase beta biosimilar (JCR Pharmaceuticals)

Glycosphingolipid

JCR Pharmaceuticals

24

Condoliase (Seikagaku corporation)

GAG

Seikagaku, Kaken Pharmaceutical Co., Ltd., Ferring Pharmaceuticals

25

Burosumab-twza

FGF23

Kyowa Hakko Kirin, Ultragenyx

26

Damoctocog alfa pegol

F10

Bayer

27

Mecapegfilgrastim

CSF3R

Jiangsu Hengrui

28

Pegfilgrastim biosimilar (Cinfa Biotech)

CSF3R

Cinfa Biotech, Mundipharma

29

Pegfilgrastim biosimilar (Sandoz)

CSF3R

Sandoz

30

Pegfilgrastim-cbqv (Coherus BioSciences)

CSF3R

Coherus Biosciences

31

Pegfilgrastim-jmdb

CSF3R

Biocon, Mylan

32

Fremanezumab

CGRP

Pfizer, Teva

33

Galcanezumab

CGRP

Eli Lilly

34

Ibalizumab-uiyk

CD4

Biogen, TaiMed Biologics, Theratechnologies

35

Moxetumomab pasudotox

CD22

AstraZeneca

36

Erenumab-aooe

CALCRL

Amgen, Novartis

37

Ravulizumab

C5

Alexion Pharmaceuticals

38

Calaspargase pegol

ASN

Shire, Servier

39

Elapegademase-lvlr

Adenosine

Leadiant Biosci

According to the forecast of IMS Health, the Chinese biopharmaceutical market will become the world’s second largest biopharmaceutical market in 2020, only next to the U.S. Then, what are the forefronts in the process? How can pharmaceutical practitioners reach new heights?

Xuanyao, an independent observer of the pharmaceutical industry, with a master’s degree in Pharmacology from China Pharmaceutical University; having successively served in the Market Department of a listed pharmaceutical enterprise in China and Marketing Department of a Global 500 foreign enterprise; currently engaging in the pharmaceutical private equity investment industry, with the WeChat account: pharmacology_cpu


-----------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.

 

Previous:Will Other Pharmaceutical Enterprises Follow Up after the Large-scale Acquisitions of “New Takeda” and “New BMS” that may Yield Successful Results?

Next:Evolving World of Pharma: Staying up to date with GMP

Related News

China's Innovative Drugs Hunt for Billion Dollar Molecule

XiaobinDecember 20, 2024

The Central Economic Work Conference in 2023 emphasized the need to promote industrial innovation through, especially by fostering new industries, new models, and new growth engines and developing new forms of productive forces.

Leading the Development of Bispecific ADCs, Multiple Chinese New Drugs Go Global

YiDecember 20, 2024

New Pathways for Innovation and Transformation of Local Pharmaceutical Companies

XiaobinDecember 20, 2024

Analysis of 39 New Biological Drugs Marketed in the World in 2018 | Pharmasources.com

Established Pharmaceutical Company Makes a High-profile Entrance with "Unlimited" R&D Investment, Signaling an Imminent Explosion in This Emerging Field

xiaobinDecember 20, 2024

Recently, Northeast Pharm announced its plan to acquire a 70% stock equity in Dingcheng Taiyuan for a total cash consideration of approximately RMB 187 million, thereby obtaining controlling stake in the company.

You may like
More>>

Zhishang Chemical Global Exporter 8006-81-3 ylang ylang essential oil 100% Cosmetic Oil Perfume Oil

Zhishang Chemical Global Exporter 8006-81-3 ylang ylang essential oil 100% Cosmetic Oil Perfume Oil
2018 Laboratory faucet

2018 Laboratory faucet
Clean pushcart used in biopharmaceutical industry

Clean pushcart used in biopharmaceutical industry
Biopharmaceutical process module GMP

Biopharmaceutical process module GMP
biopharmaceutical process module gmp

biopharmaceutical process module gmp
C 6000 global standards Package 2/10

C 6000 global standards Package 2/10
2018 Lint Free Reusable Cleanroom Cleaning Mop

2018 Lint Free Reusable Cleanroom Cleaning Mop

Ac-Phe-OH/2018-61-3

Ac-Phe-OH/2018-61-3
2018 Cleaning Uniform

2018 Cleaning Uniform
Dexamethasone IP2018

Dexamethasone IP2018

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service